involveconference2 121120053215-phpapp02
DESCRIPTION
Involve ConferenceTRANSCRIPT
![Page 1: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/1.jpg)
Avoiding waste in research:the role of public involvement
Iain ChalmersCoordinator, James Lind Initiative
‘Putting people first in research’INVOLVE Conference
Nottingham, 13 November 2012
![Page 2: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/2.jpg)
The skeletons in academic medicine’s cupboards
![Page 3: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/3.jpg)
Low priority questions addressed
Important outcomes not assessed
Clinicians and patients not involved in setting research agendas
Questions relevantto clinicians &
patients?
Over 50% studies designed without reference to systematic reviews of existing evidence
Over 50% of studies fail to take adequate steps to reduce biases, e.g. unconcealed treatment allocation
Appropriate design and methods?
Over 50% of studies never published in full
Biased under-reporting of studies with disappointing results
Accessible full publication?
Over 30% of trial interventions not sufficiently described
Over 50% of planned study outcomes not reported
Most new research not interpreted in the context of systematic assessment of other relevant evidence
Unbiased and usable report?
50%
85% Research waste = over $85 Billion / year
50%
50%
![Page 4: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/4.jpg)
Mismatch of patients’ and researchers’ priorities for osteoarthritis of the knee
Tallon, Chard and Dieppe. Lancet, 2000.
![Page 5: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/5.jpg)
Priority treatment outcome from a survey of patients with rheumatoid arthritis was not pain
It was fatigue
![Page 6: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/6.jpg)
![Page 7: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/7.jpg)
For every ongoing trial being conducted within the NHS, the UK Clinical Trials Gateway should aim to provide access to: a lay summary the patient information sheet the WHO 20-item dataset the protocol, with links to the systematic review(s) showing why the trial is needed the trial website (if one exists)
![Page 8: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/8.jpg)
Reliable, user-friendly information about specific ongoing clinical trials is
still NOT generally available
![Page 9: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/9.jpg)
![Page 10: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/10.jpg)
2003-The James Lind Initiative
Funded by the National Institute of Health Research and the Medical Research Council
“to promote acknowledgement of uncertainties about the effects of treatments, and
research to address them.”
![Page 11: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/11.jpg)
Programme of work of The James Lind Initiative
1. Identifying and publishing uncertainties about the effects of treatments: UK Database of Uncertainties about the Effects of Treatments
2. Identifying patients’ and clinicians’ shared priorities for research about the effects of treatments: James Lind Alliance
3. Explaining and illustrating the development of fair tests of treatments in health care: James Lind Library and Testing Treatments
![Page 12: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/12.jpg)
The UK Database of Uncertainties about the Effects of Treatments
Established to publish uncertainties about the effects of treatments which cannot currently be answered by referring to relevant and reliable, up-to-date systematic reviews of existing
research evidence
![Page 13: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/13.jpg)
UK DUETs draws on three main sources
•Patients', carers' and clinicians' unanswered
questions about the effects of treatments
•Research recommendations in reports of
systematic reviews and clinical guidelines
•Ongoing research, both systematic reviews in
preparation and new 'primary' studies
![Page 14: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/14.jpg)
![Page 15: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/15.jpg)
Programme of work of The James Lind Initiative
1. Identifying and publishing uncertainties about the effects of treatments: UK Database of Uncertainties about the Effects of Treatments
2. Identifying patients’ and clinicians’ shared priorities for research about the effects of treatments: James Lind Alliance
3. Explaining and illustrating the development of fair tests of treatments in health care: James Lind Library and Testing Treatments
![Page 16: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/16.jpg)
To increase the focus of the therapeutic research agenda on questions and priorities shared by patients and clinicians.
To promote Priority Setting Partnerships involving patients and clinicians to identify and promote their shared priorities for therapeutic research.
To increase general awareness and understanding of the need to refocus the therapeutic research agenda.
![Page 17: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/17.jpg)
Sally CroweChair, JLA Monitoring & Implementation Group
Lester FirkinsChair, JLA Strategy
& Development Group
Patricia AtkinsonAdministrator,JLA Secretariat
Katherine CowanEditor, JLA Guidebook
![Page 18: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/18.jpg)
Involving patients, carers and clinicians in research priority setting
The JLA’s principles•Inclusive
•Balance of perspectives•Accessible to all
•Supportive•Recognising a range of capacities and skills
•Transparent and democratic•Data sharing•Agreed protocol•Declaration of interests•Neutral facilitation •Communication and feedback
![Page 19: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/19.jpg)
JLA Priority Setting Partnerships
Completed Current •Asthma•Urinary incontinence•Vitiligo•Prostate cancer•Schizophrenia•Type 1 diabetes•ENT aspects of balance•Life after stroke•Eczema•Tinnitus•Cleft lip and palate
•Acne•Childhood disability •Dementia•Dialysis•Head and neck cancer•Inflammatory bowel disease•Lyme disease•Multiple sclerosis •Pressure ulcers•Pre-term birth•Sight loss and vision
![Page 20: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/20.jpg)
Research priority themes [across asthma,
incontinence, vitiligo, eczema, stroke, prostate cancer, schizophrenia, aspects of balance, and type 1 diabetes]
• Assessment of long-term effects (wanted and unwanted) of treatments
• Assessment of safety and adverse effects of treatments
• Assessment of complementary and non-prescribed treatments
• Assessment of strategies to improve early diagnosis and treatments, and harmonisation of practice
• Assessment of the effectiveness and safety of self-care
![Page 21: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/21.jpg)
Low priority questions addressed
Important outcomes not assessed
Clinicians and patients not involved in setting research agendas
Questions relevantto clinicians &
patients?
Over 50% studies designed without reference to systematic reviews of existing evidence
Over 50% of studies fail to take adequate steps to reduce biases, e.g. unconcealed treatment allocation
Appropriate design and methods?
Over 50% of studies never published in full
Biased under-reporting of studies with disappointing results
Accessible full publication?
Over 30% of trial interventions not sufficiently described
Over 50% of planned study outcomes not reported
Most new research not interpreted in the context of systematic assessment of other relevant evidence
Unbiased and usable report?
50%
85% Research waste = over $85 Billion / year
50%
50%
![Page 22: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/22.jpg)
Publication (2007) after registration (1999)
Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM (2009). Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med 6(9): e1000144.
Country
Size
Phase
Funder
![Page 23: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/23.jpg)
“Studies that report positive or significant resultsare more likely to be published and outcomes that are statistically significant have higher oddsof being fully reported.”
PLoS ONE, August 2008;3:e3081
![Page 24: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/24.jpg)
![Page 25: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/25.jpg)
Alessandro Liberati
![Page 26: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/26.jpg)
Because research results have not been made public…
…patients have suffered and died unnecessarily and resources for health care and health research have been wasted.
![Page 27: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/27.jpg)
TGN1412
TGN 1412
![Page 28: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/28.jpg)
![Page 29: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/29.jpg)
![Page 30: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/30.jpg)
![Page 31: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/31.jpg)
![Page 32: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/32.jpg)
![Page 33: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/33.jpg)
![Page 34: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/34.jpg)
What is the position of the Academy of Medical Sciences?
![Page 35: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/35.jpg)
2006 letter to Prof John Bell, President, Academy of Medical Sciences
![Page 36: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/36.jpg)
![Page 37: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/37.jpg)
What should be done?
The public needs to be made aware of how the resources they provide for research are being wasted.
The public needs to hold the research community to account, and be critically involved in research, from agenda setting to dissemination of results.
![Page 38: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/38.jpg)
Programme of work of The James Lind Initiative
1. Identifying and publishing uncertainties about the effects of treatments: UK Database of Uncertainties about the Effects of Treatments
2. Identifying patients’ and clinicians’ shared priorities for research about the effects of treatments: James Lind Alliance
3. Explaining and illustrating the development of fair tests of treatments in health care: James Lind Library and Testing Treatments
![Page 39: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/39.jpg)
www.jameslindlibrary.org
![Page 40: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/40.jpg)
![Page 41: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/41.jpg)
…but only if it meets scientific and ethical principles
Promote research on the effects of treatments…
![Page 42: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/42.jpg)
www.testingtreatments.org
![Page 43: Involveconference2 121120053215-phpapp02](https://reader035.vdocuments.us/reader035/viewer/2022070321/558bb4d3d8b42aab1e8b469b/html5/thumbnails/43.jpg)
“Bad Science introduces the basic scientific principles to help everyone become a more effective bullshit
detector.”